The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VTVT | +89.84% | -67.46% | -20.11% | -93% |
| S&P | +15.58% | +78.13% | +12.24% | +230% |
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
No news articles found for vTv Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$2.00K | 90.9% |
| Gross Margin | -29.41% | 0.0% |
| Market Cap | $61.11M | 85.2% |
| Market Cap / Employee | $2.66M | 0.0% |
| Employees | 23 | 0.0% |
| Net Income | -$10,345.00K | -77.1% |
| EBITDA | -$10,697.00K | -65.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $98.50M | 137.0% |
| Accounts Receivable | $62.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $360.00K | 98.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -32.90% | 30.1% |
| Return On Invested Capital | 53.33% | -37.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,830.00K | 24.7% |
| Operating Free Cash Flow | -$4,830.00K | 24.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.40 | 3.71 | 4.95 | 22.13 | 1004.59% |
| Price to Sales | 89.38 | 6706.76 | 5812.12 | 11065.07 | 14849.81% |
| Price to Tangible Book Value | 2.40 | 3.71 | 4.95 | 22.13 | 1004.59% |
| Enterprise Value to EBITDA | -11.59 | -12.94 | -9.41 | -8.41 | 53.34% |
| Return on Equity | -2570.6% | -130.2% | -203.3% | -54.9% | - |
| Total Debt | $169.00K | $125.00K | $79.00K | $360.00K | 69.01% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
